Literature DB >> 25613108

Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model.

Gaetano Ruocco1, Behar Cekorja2, Paola Rottoli2, Rosa Metella Refini2, Marco Pellegrini1, Cristina Di Tommaso1, Gabriele Del Castillo1, Beatrice Franci1, Ranuccio Nuti1, Alberto Palazzuoli3.   

Abstract

BACKGROUND: This study evaluated the role of echocardiography and BNP in patients with interstitial lung disease (ILD), to identify those with PH and RV dysfunction. The aims of this study were: 1-to evaluate the accuracy of an algorithm including BNP, DLCO and echocardiographic measurements to identify PH and RV dysfunction; 2- to evaluate BNP and Echo values concordance in relation to right catheterization measurement.
METHODS: We analyzed 113 patients with diagnosis of ILD. Echo examination included: Pulmonary systolic, diastolic and mean Arterial Pressure (PAPs, PAPd, PAP mean), End-Diastolic and End-Systolic right ventricle diameters, Inferior Caval Vein diameter, and Tricuspid Annular Plane Systolic Excursion (TAPSE). Patients revealing increased PAPs at echocardiography underwent to catheterization.
RESULTS: Patients with PAPs > 40 mm Hg (37 patients), PAPmean ≥ 25 mm Hg (23 patients) and PAPd ≥ 20 mm Hg showed BNP increased (157 ± 96 vs 16 ± 14 pg/ml p = 0.004; 201 ± 120 vs 28 ± 17 pg/mL; 124 ± 88 vs 23 ± 18 pg/ml p < 0.001) as patients with TAPSE ≤16 mm (25 patients) (145 ± 104 vs 26 ± 21 pg/ml p < 0.001). In catheterized patients (37 patients) BNP was increased in patients with invasive PAPs > 40 mm Hg (165 ± 112 vs 29 ± 14 pg/ml p < 0.02), as well as in patients with Wedge pressure > 14 mm Hg (199 + 153 vs 54 + 39 pg/mL; p = 0.01). ROC Curve analysis showed that elevated values of BNP, PAPs, PAP mean are able to assess PH. On the other hand, lower values of DLCO (<40%) and TAPSE (≤16 mm) detect PH. Logistic regression analysis of the previous parameters, confirmed their diagnostic role in PH detection.
CONCLUSIONS: In patients with ILD, an algorithm including BNP, DLCO and echocardiography could be useful for non invasive screening of PH. CLINICAL TRIAL REGISTRATION NAME AND NUMBER: ARTEMIS-HP trial; ID number: NCT00879229.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BNP; Diagnostic methods; Interstitial lung disease; Pulmonary hypertension

Mesh:

Substances:

Year:  2015        PMID: 25613108     DOI: 10.1016/j.rmed.2014.12.011

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

1.  The Utility of Brain Natriuretic Peptide in Patients Undergoing an Initial Evaluation for Pulmonary Hypertension.

Authors:  Sanjana Rao; Benjamin Daines; Omid Hosseini; Victor Test; Kenneth Nugent
Journal:  J Community Hosp Intern Med Perspect       Date:  2022-05-02

2.  Brain natriuretic peptide reflects individual variation in hydration status in hemodialysis patients.

Authors:  Jenny Stenberg; Jan Melin; Magnus Lindberg; Hans Furuland
Journal:  Hemodial Int       Date:  2019-03-07       Impact factor: 1.812

Review 3.  Diagnosis of Acute Heart Failure in the Emergency Department: An Evidence-Based Review.

Authors:  Brit Long; Alex Koyfman; Michael Gottlieb
Journal:  West J Emerg Med       Date:  2019-10-24

4.  The role of the combination of echo-HRCT score as a tool to evaluate the presence of pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  Rosa Metella Refini; Gloria Bettini; Esmeralda Kacerja; Paolo Cameli; Miriana d'Alessandro; Laura Bergantini; Ferdinando De Negri; Paola Rottoli; Piersante Sestini; Elena Bargagli; Maria Antonietta Mazzei
Journal:  Intern Emerg Med       Date:  2020-11-05       Impact factor: 3.397

Review 5.  Pulmonary hypertension complicating pulmonary sarcoidosis.

Authors:  M P Huitema; J C Grutters; B J W M Rensing; H J Reesink; M C Post
Journal:  Neth Heart J       Date:  2016-06       Impact factor: 2.380

6.  Diagnostic Value of Selected Echocardiographic Variables to Identify Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease.

Authors:  A Tidholm; K Höglund; J Häggström; I Ljungvall
Journal:  J Vet Intern Med       Date:  2015-09-14       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.